At this time, navitoclax targeting CAFs may achieve therapeutic effects by reducing the proliferative response of connective tissue, ECM deposition [136], and inhibiting tumor growth, which opens up new avenues for tumor treatment. Here, TBX1 is linked to neoplasm.